Microparticle generation and leucocyte death in Shiga toxin-mediated HUS

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2768-2775

  Ge, Shuwang ^a   Hertel, Barbara ^a   Emden, Sang Hi ^a   Beneke, Jan ^a   Menne, Jan ^a   Haller, Hermann ^a   Von Vietinghoff, Sibylle ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

complement inhibition; leucocyte apoptosis; microparticles; plasma exchange; STEC HUS

Indexed keywords

ECULIZUMAB; SHIGA TOXIN;

ADULT; APOPTOSIS; ARTICLE; CELL DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; INTENSIVE CARE UNIT; LEUKOCYTE; LEUKOCYTE MICROPARTICLE; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELLS, CULTURED; COHORT STUDIES; DISEASE OUTBREAKS; ESCHERICHIA COLI INFECTIONS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MONOCYTES; NECROSIS; SHIGA TOXIN; SHIGA-TOXIGENIC ESCHERICHIA COLI; TERTIARY CARE CENTERS;

EID: 84864407746     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr748     Document Type: Article

References (40)

1. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431.
2. Fakhouri F, Fremeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. Nat Clin Pract Nephrol 2007; 3: 679-687.
3. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008; 59: 293-309.
4. Frank C, Werber D, Cramer JP et al. Epidemic profile of Shigatoxin-producing Escherichia coli O104:H4 outbreak in Germany-preliminary report. N Engl J Med 2011; 365: 1771-1780.
5. Daniel L, Fakhouri F, Joly D et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006; 69: 1416-1423.
6. Mallat Z, Benamer H, Hugel B et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
7. Stahl AL, Sartz L, Karpman D. Complement activation on plateletleukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117: 5503-5513.
8. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000; 95: 1317-1323.
9. Mack M, Kleinschmidt A, Bruhl H et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6: 769-775.
10. Salanova B, Choi M, Rolle S et al. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. J Biol Chem 2007; 282: 27960-27969.
11. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116: 3211-3219.
12. Zernecke A, Bidzhekov K, Noels H et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81
13. Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood 1991; 78: 2880-2886.
14. Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924.
15. Orth D, Khan AB, Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182: 6394-6400.
16. Tesh VL. Induction of apoptosis by Shiga toxins. Future Microbiol 2010; 5: 431-453.
17. Brigotti M, Carnicelli D, Ravanelli E et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol 2008; 84: 1019-1027.
18. Brigotti M, Tazzari PL, Ravanelli E et al. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. J Leukoc Biol 2010; 88: 201-210.
19. te Loo DM, Monnens LA, van Der Velden TJ et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95: 3396-3402.
20. Te Loo DM, van Hinsbergh VW, van den Heuvel LP et al. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 2001; 12: 800-806.
21. Lee MS, Cherla RP, Leyva-Illades D et al. Bcl-2 regulates the onset of Shiga toxin 1-induced apoptosis in THP-1 cells. Infect Immun 2009; 77: 5233-5244.
22. Liu J, Akahoshi T, Sasahana T et al. Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7. Infect Immun 1999; 67: 6203-6205.
23. Flagler MJ, Strasser JE, Chalk CL et al. Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun 2007; 75: 760-765.
24. Michael M, Elliott EJ, Craig JC et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53: 259-272.
25. Michael M, Elliott EJ, Ridley GF et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009CD003595
26. Dundas S, Murphy J, Soutar RL et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354: 1327-1330.
27. Pu JJ, Mukhina G, Wang H et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol 2011; 87: 37-45.
28. Al-Akash SI, Almond PS, Savell VH, Jr et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with c3 gene mutation. Pediatr Nephrol 2011; 26: 613-619.
29. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546.
30. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1326.
31. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.
32. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563.
33. Stahl AL, Sartz L, Nelsson A et al. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 2009; 4: e6990
34. Morel O, Toti F, Jesel L et al. Mechanisms of microparticle generation: on the trail of the mitochondrion!. Semin Thromb Hemost 2010; 36: 833-844.
35. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
36. Taylor CM, Machin S, Wigmore SJ et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the united kingdom. Br J Haematol 2010; 148: 37-47.
37. Colic E, Dieperink H, Titlestad K et al. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern denmark: an observational study. Lancet 2010; 378: 1089-1093.
38. Rank A, Nieuwland R, Crispin A et al. Clearance of platelet microparticles in vivo. Platelets 2011; 22: 111-116.
39. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180.
40. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 1191-1197.